Literature DB >> 22473501

Do not treat from CIS onset: evaluate disease course and prognosis first--no (treat!).

Mark S Freedman1.   

Abstract

Mesh：

Year:  2012        PMID： 22473501     DOI： 10.1177/1352458512440605

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  2 in total

1.  Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alessandra Lugaresi; Maria di Ioia; Daniela Travaglini; Erika Pietrolongo; Eugenio Pucci; Marco Onofrj
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

2.  A multi-biomarker follow-up study of patients with multiple sclerosis.

Authors:  Morten Stilund; Mikkel Carstensen Gjelstrup; Tove Christensen; Holger Jon Møller; Thor Petersen
Journal:  Brain Behav       Date:  2016-07-11       Impact factor: 2.708
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.